Item 7.01 Regulation FD Disclosure.
The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On
Forward- Looking Statements
This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the collaboration with Resilience, the potential of its LNC platform delivery technology, and the future development of its product candidates, the Company's ability to identify and pursue development, licensing and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements.
These statements may be identified by the use of forward-looking expressions,
including, but not limited to, "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These statements
involve known and unknown risks, uncertainties and other factors which may cause
actual results to be materially different from any future results expressed or
implied by the forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, including, but not limited to,
the Company's ability to obtain additional capital to meet its liquidity needs
on acceptable terms, or at all, including the additional capital which will be
necessary to complete the clinical trials of our product candidates; the ability
to successfully complete research and further development and commercialization
of our product candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our ability to
protect the Company's intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the regulatory
landscape or the imposition of regulations that affect the Company's products;
and the other factors listed under "Risk Factors" in our filings with the
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 99.1 Press Release, datedJanuary 12, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -.2-
© Edgar Online, source